Albany Molecular Research (AMRI), a CRO based in Albany, N.Y., has signed a collaborative agreement with Buffalo, N.Y.-based biotechnology company HarkerBIO to co-market their structure-based drug discovery services to global pharmaceutical and biotechnology clients. AMRI gains access to HarkerBIO's differentiated high-resolution, structure-determination experience and capabilities. HarkerBIO's customers will be able to access and benefit from AMRI's global capabilities, including their integrated drug discovery platforms and solutions.
Aimed at accelerating decision making and success in the translation from discovery to the clinic, the alliance with HarkerBIO is an early example of the types of partnerships AMRI is creating. AMRI's new discovery center is co-located on the Buffalo Niagara Medical Campus and is part of the larger commitment by the state of New York.
Michael A. Luther, senior vice president, discovery and development, AMRI, said, "Our strategy is to leverage and build creative and effective collaborations with on-campus and off-campus partners from global pharma to academia including technology partners within this unique public-private environment."
Financial terms of the agreement have not been disclosed.